“Banks may be underperforming due to investors wanting to see how new management functions, while IT companies benefit from new leaders bringing in business relationships. We have consumer tech and fintech companies in our portfolios and there is expectation of growth and better margins as they transition to profitability. The pharmaceuticals sector is overvalued.”
Subscribe To Our Free Newsletter |